119 related articles for article (PubMed ID: 29376757)
1. Bone-targeting dendrimer for the delivery of methotrexate and treatment of bone metastasis.
Yamashita S; Katsumi H; Sakane T; Yamamoto A
J Drug Target; 2018 Nov; 26(9):818-828. PubMed ID: 29376757
[TBL] [Abstract][Full Text] [Related]
2. [PEGylated polyamidoamine dendrimer/methotrexate complex: pharmacokinetics and anti-tumor activity in normal and tumor-bearing rodents].
Kong SY; Tang GT; Pei YY; Jiang YY
Yao Xue Xue Bao; 2009 Jan; 44(1):85-90. PubMed ID: 19350828
[TBL] [Abstract][Full Text] [Related]
3. Calcium phosphate nanoparticles functionalized with alendronate-conjugated polyethylene glycol (PEG) for the treatment of bone metastasis.
Chu W; Huang Y; Yang C; Liao Y; Zhang X; Yan M; Cui S; Zhao C
Int J Pharm; 2017 Jan; 516(1-2):352-363. PubMed ID: 27887884
[TBL] [Abstract][Full Text] [Related]
4. Development of PEGylated carboxylic acid-modified polyamidoamine dendrimers as bone-targeting carriers for the treatment of bone diseases.
Yamashita S; Katsumi H; Hibino N; Isobe Y; Yagi Y; Kusamori K; Sakane T; Yamamoto A
J Control Release; 2017 Sep; 262():10-17. PubMed ID: 28710004
[TBL] [Abstract][Full Text] [Related]
5. Dendrimer-based micelles with highly potent targeting to sites of active bone turnover for the treatment of bone metastasis.
Yamashita S; Katsumi H; Shimizu E; Nakao Y; Yoshioka A; Fukui M; Kimura H; Sakane T; Yamamoto A
Eur J Pharm Biopharm; 2020 Dec; 157():85-96. PubMed ID: 33039547
[TBL] [Abstract][Full Text] [Related]
6. Development of PEGylated aspartic acid-modified liposome as a bone-targeting carrier for the delivery of paclitaxel and treatment of bone metastasis.
Yamashita S; Katsumi H; Hibino N; Isobe Y; Yagi Y; Tanaka Y; Yamada S; Naito C; Yamamoto A
Biomaterials; 2018 Feb; 154():74-85. PubMed ID: 29120820
[TBL] [Abstract][Full Text] [Related]
7. Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms.
Clementi C; Miller K; Mero A; Satchi-Fainaro R; Pasut G
Mol Pharm; 2011 Aug; 8(4):1063-72. PubMed ID: 21608527
[TBL] [Abstract][Full Text] [Related]
8. Octreotide-conjugated PAMAM for targeted delivery to somatostatin receptors over-expressed tumor cells.
Peng J; Qi X; Chen Y; Ma N; Zhang Z; Xing J; Zhu X; Li Z; Wu Z
J Drug Target; 2014 Jun; 22(5):428-38. PubMed ID: 24437350
[TBL] [Abstract][Full Text] [Related]
9. Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines.
Gurdag S; Khandare J; Stapels S; Matherly LH; Kannan RM
Bioconjug Chem; 2006; 17(2):275-83. PubMed ID: 16536456
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers.
Kaminskas LM; Kelly BD; McLeod VM; Boyd BJ; Krippner GY; Williams ED; Porter CJ
Mol Pharm; 2009; 6(4):1190-204. PubMed ID: 19453158
[TBL] [Abstract][Full Text] [Related]
11. Capping methotrexate α-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers.
Kaminskas LM; Kelly BD; McLeod VM; Sberna G; Boyd BJ; Owen DJ; Porter CJ
Mol Pharm; 2011 Apr; 8(2):338-49. PubMed ID: 21171585
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylated Serine-Modified Polyamidoamine Dendrimer as an Osteoid Surface-Targeting Drug Carrier.
Yamashita S; Katsumi H; Sakane T; Yamamoto A
Mol Pharm; 2022 Jul; 19(7):2573-2582. PubMed ID: 35666687
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonate-functionalized coordination polymer nanoparticles for the treatment of bone metastatic breast cancer.
He Y; Huang Y; Huang Z; Jiang Y; Sun X; Shen Y; Chu W; Zhao C
J Control Release; 2017 Oct; 264():76-88. PubMed ID: 28842315
[TBL] [Abstract][Full Text] [Related]
14. PEGylated PAMAM dendrimers as a potential drug delivery carrier: in vitro and in vivo comparative evaluation of covalently conjugated drug and noncovalent drug inclusion complex.
Jiang YY; Tang GT; Zhang LH; Kong SY; Zhu SJ; Pei YY
J Drug Target; 2010 Jun; 18(5):389-403. PubMed ID: 20055559
[TBL] [Abstract][Full Text] [Related]
15. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
16. Bone-targeted PAMAM nanoparticle to treat bone metastases of lung cancer.
Bai SB; Cheng Y; Liu DZ; Ji QF; Liu M; Zhang BL; Mei QB; Zhou SY
Nanomedicine (Lond); 2020 Apr; 15(9):833-849. PubMed ID: 32163008
[No Abstract] [Full Text] [Related]
17. Lactoferrin-conjugated dendritic nanoconstructs for lung targeting of methotrexate.
Kurmi BD; Gajbhiye V; Kayat J; Jain NK
J Pharm Sci; 2011 Jun; 100(6):2311-20. PubMed ID: 21491447
[TBL] [Abstract][Full Text] [Related]
18. Molecular Design of Bisphosphonate-Modified Proteins for Efficient Bone Targeting In Vivo.
Katsumi H; Sano J; Nishikawa M; Hanzawa K; Sakane T; Yamamoto A
PLoS One; 2015; 10(8):e0135966. PubMed ID: 26287482
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancer.
Ye WL; Zhao YP; Li HQ; Na R; Li F; Mei QB; Zhao MG; Zhou SY
Sci Rep; 2015 Sep; 5():14614. PubMed ID: 26419507
[TBL] [Abstract][Full Text] [Related]
20. Peptide-conjugated polyamidoamine dendrimer as a nanoscale tumor-targeted T1 magnetic resonance imaging contrast agent.
Han L; Li J; Huang S; Huang R; Liu S; Hu X; Yi P; Shan D; Wang X; Lei H; Jiang C
Biomaterials; 2011 Apr; 32(11):2989-98. PubMed ID: 21277017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
